GlassScriptPhysician profile
Jasmine E Melton
NPI 1386530129
$2,782.86
in general payments reported to CMS, 2019-2025
17 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $524.58 | 2025 | Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $365.39 | 2025 | Lokelma, Breztri |
| Novo Nordisk INC | $289.89 | 2025 | Wegovy |
| Genentech, INC. | $142.29 | 2025 | |
| Neurocrine Biosciences, INC. | $136.76 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $132.35 | 2025 | Cobenfy |
| Phathom Pharmaceuticals, INC. | $125.24 | 2025 | Voquezna |
| Astellas Pharma US INC | $121.82 | 2025 | Veozah |
| Lilly USA, LLC | $120.47 | 2023 | Mounjaro |
| Stryker Corporation | $119.92 | 2025 | Clarifix, Xpress Loprofile |
| Aurinia Pharma U.S., INC. | $119.70 | 2025 | Lupkynis |
| Glaxosmithkline, LLC. | $119.02 | 2025 | Shingrix |
| Biogen, INC. | $118.10 | 2025 | Zurzuvae |
| Madrigal Pharmaceuticals | $115.92 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $101.18 | 2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $82.36 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $47.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Melton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.